New Stars in the Sky of Treatment for Early Breast Cancer

New England Journal of Medicine

Volumn 350, Issue 11, 2004, Pages 1140-1142

  Piccart Gebhart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROSTANE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE; AROMATASE INHIBITOR; EXEMESTANE; FULVESTRANT; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CARCINOMA; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDICATION; DRUG MECHANISM; DRUG WITHDRAWAL; EARLY CANCER; EDITORIAL; ENZYME INHIBITION; FEMALE; HUMAN; MOLECULAR MECHANICS; NEOPLASM; POSTMENOPAUSE; PREOPERATIVE CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOEMBOLISM; UTERUS DISEASE;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; TAMOXIFEN;

EID: 1542346215     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048037     Document Type: Editorial

References (13)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104-7.
2. Cuzick J, Powles T, Veronesi V, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-67.
4. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447S-454S.
5. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350: 1081-92.
6. Dixon JM. Exemestane and aromatase inhibitors in the management of advanced breast cancer. Expert Opin Pharmacother 2004; 5:307-16.
7. Brueggemeier RW. Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res Treat 2002;74: 177-85.
8. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
9. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
10. Baum M, Buzdar AU, Cuzik J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. [Erratum, Lancet 2002;360:1520.]
11. Baum M, Buzdar AU, Cuzik J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. [Erratum, Lancet 2002;360:1520.]
12. Bryant J, Wolmark N. Letrozole after tamoxifen for breast cancer - what is the price of success? N Engl J Med 2003;349:1855-7.
13. Piccart MJ, Goldhirsch A, Straehle C. The Breast International Group: a new spirit of collaboration in breast cancer research for the new millennium. Eur J Cancer 2000;36:1733-6.